International Urology and Nephrology

, Volume 40, Issue 1, pp 97–104 | Cite as

Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy

  • Thomas Nelius
  • Tobias Klatte
  • Werner de Riese
  • Stephanie Filleur
Original Article

Abstract

Objectives

The intention of this study is to describe the impact and underlying potential basis of the prostate-specific antigen (PSA) flare-up phenomenon in patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel-based chemotherapy.

Methods

We retrospectively identified 74 consecutive patients who received docetaxel/estramustine-based chemotherapy at our institution. Patients were evaluated based on modified criteria from the Prostate-Specific Antigen Working Group regarding survival and toxicity. Additionally, two androgen receptor mutations derived from patients with advanced disease were analyzed for promiscuous transactivation activity.

Results

The 74 patients were stratified into four groups: response, partial response, flare-up-initial PSA elevation, and progression. Median survival in the flare-up group (n = 8) was 20 months and did not differ from the response group (p = 0.564). The flare-up group showed a maximum PSA elevation from baseline between 3.4 and 28.3% (between three and six weeks) followed by PSA decline ≥50% from the baseline level in seven of the eight patients. The androgen receptor mutations AR877 and AR715 displayed a 37.5- and 5.2-fold increase in transactivation activity by progesterone and a 12.6- and 5.4-fold increase by estrogen compared to the ARWT, respectively.

Conclusions

A considerable portion of HRPC patients experience an initial PSA flare-up under systemic chemotherapy. In this study, occurence of flare-up phenomenon did not impact survival. Chemotherapy should be continued a minimum of six weeks before removing patients from a docetaxel-based regimen. We showed evidence that co-medication with dexamethasone/prednisolone and/or estramustine itself can induce an initial PSA flare-up via androgen receptor mutations.

Keywords

Androgen receptor Docetaxel Estramustine Hormone-refractory prostate cancer Prostate-specific antigen 

References

  1. 1.
    Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRefGoogle Scholar
  2. 2.
    Crawford ED, Eisenberger MA, McLeod DG et al (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424PubMedCrossRefGoogle Scholar
  3. 3.
    Eisenberger MA, Blumenstein BA, Crawford ED et al (1998) Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036–1042PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54:8–29PubMedGoogle Scholar
  5. 5.
    Yagoda A, Petrylak D (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71:1098–1109PubMedCrossRefGoogle Scholar
  6. 6.
    Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520PubMedCrossRefGoogle Scholar
  7. 7.
    Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512PubMedCrossRefGoogle Scholar
  8. 8.
    Oudard S, Banu E, Beuzeboc P et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23:3343–3351PubMedCrossRefGoogle Scholar
  9. 9.
    Noguchi K, Uemura H, Harada M et al (2001) Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist. Int J Clin Oncol 6:29–33PubMedCrossRefGoogle Scholar
  10. 10.
    Fossa SD, Vaage S, Letocha H et al (2002) Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC)–delayed response and flare phenomenon should be considered. Scand J Urol Nephrol 36:34–39PubMedGoogle Scholar
  11. 11.
    Heidenreich A, Sommer F, Ohlmann CH et al (2004) Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101:948–956PubMedCrossRefGoogle Scholar
  12. 12.
    Olbert PJ, Hegele A, Kraeuter P et al (2006) Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs 17:993–996PubMedCrossRefGoogle Scholar
  13. 13.
    Bubley GJ, Carducci M, Dahut W et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461–3467PubMedGoogle Scholar
  14. 14.
    Kreis W, Budman DR, Fetten J et al (1999) Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 10:33–38PubMedCrossRefGoogle Scholar
  15. 15.
    Hudes GR, Nathan F, Khater C et al (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156–3163PubMedGoogle Scholar
  16. 16.
    Pienta KJ, Redman B, Hussain M et al (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005–2012PubMedGoogle Scholar
  17. 17.
    Nelius T, Reiher F, Lindenmeir T et al (2005) Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie 28:573–578PubMedCrossRefGoogle Scholar
  18. 18.
    Kelly WK, Scher HI, Mazumdar M et al (1993) Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607–615PubMedGoogle Scholar
  19. 19.
    Sridhara R, Eisenberger MA, Sinibaldi VJ et al (1995) Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944–2953PubMedGoogle Scholar
  20. 20.
    Petrylak DP, Scher HI, Li Z et al (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70:2870–2878PubMedCrossRefGoogle Scholar
  21. 21.
    Roessner M, de Wit R, Tannock IF, Yateman N, Yao S-L, Yver A, Eisenberger MA, on behalf of the TAX 327 Investigators (2005) Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer. J Clin Oncol 23:391: abstract 4554Google Scholar
  22. 22.
    Liu AY, True LD, LaTray L et al (1999) Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate 40:192–199PubMedCrossRefGoogle Scholar
  23. 23.
    van der Poel HG, Oosterhof GO, Schaafsma HE et al (1997) Intratumoral nuclear morphologic heterogeneity in prostate cancer. Urology 49:652–657PubMedCrossRefGoogle Scholar
  24. 24.
    Taplin ME, Rajeshkumar B, Halabi S et al (2003) Androgen receptor mutations in androgen-independent prostate cancer: cancer and leukemia group B study 9663. J Clin Oncol 21:2673–2678PubMedCrossRefGoogle Scholar
  25. 25.
    Brinkmann AO, Trapman J (2000) Prostate cancer schemes for androgen escape. Nat Med 6:628–629PubMedCrossRefGoogle Scholar
  26. 26.
    Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34–45PubMedCrossRefGoogle Scholar
  27. 27.
    Yeh S, Hu YC, Rahman M et al (2000) Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Nat Acad Sci U S A 97:11256–11261PubMedCrossRefGoogle Scholar
  28. 28.
    Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175–200PubMedCrossRefGoogle Scholar
  29. 29.
    Godoy-Tundidor S, Hobisch A, Pfeil K et al (2002) Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells. Clin Cancer Res 8:2356–2361PubMedGoogle Scholar
  30. 30.
    Lu ML, Schneider MC, Zheng Y et al (2001) Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 276:13442–13451PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2007

Authors and Affiliations

  • Thomas Nelius
    • 1
    • 2
  • Tobias Klatte
    • 2
    • 3
  • Werner de Riese
    • 1
  • Stephanie Filleur
    • 1
  1. 1.Department of UrologyTexas Tech University Health Sciences CenterLubbockUSA
  2. 2.Department of UrologyOtto-von-Guericke-University MagdeburgMagdeburgGermany
  3. 3.Department of UrologyDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations